Hepatic metabolism of chlorinated derivatives of bisphenol A ($ Cl_{x} $BPA) and interspecies differences between rats and humans
Abstract During chlorination treatments of drinking water, aqueous bisphenol A (BPA) can react with chlorine to form chlorinated derivatives of BPA (mono, di, tri and tetra-chlorinated derivatives) or $ Cl_{x} $BPA. These emerging substances are endocrine disruptors associated with obesity, type II diabetes (TD2M) and myocardial infarction. $ Cl_{x} $BPA are present in different human biological matrices but their toxicokinetics remain unknown. The aim of this study was to measure and compare the metabolic kinetics in the liver of four $ Cl_{x} $BPA (ClBPA, $ Cl_{2} $BPA, $ Cl_{3} $BPA and $ Cl_{4} $BPA) between compounds and between species (Sprague–Dawley rats vs humans). To estimate their metabolic constants (Vmax, Km, Intrinsic clearance), metabolic assays were performed in hepatocyte suspensions. Assays revealed that metabolic constants of $ Cl_{x} $BPA can greatly vary depending on substances and species. While ClBPA and $ Cl_{2} $BPA show similar unbound intrinsic clearances (ClintU) in rat incubation media, values for $ Cl_{3} $BPA and $ Cl_{4} $BPA are very different (3.109 and 0.684 mL/min/106 hepatocytes, respectively). Unlike in rats, human results are quite different as $ Cl_{3} $BPA and $ Cl_{4} $BPA have similar unbound intrinsic clearances, while ClBPA and $ Cl_{2} $BPA diverge (0.350 and 1.363 mL/min/106 hepatocytes, respectively). In both species, $ Cl_{2} $BPA and Cl3BPA have relatively similar clearances, and ClBPA is very different from $ Cl_{4} $BPA. Although we quantified the proportion of sulfo- and glucurono-metabolites, other metabolites may have been formed (e.g., glutathione, disulfate, or oxidative metabolites). This study showed that chlorination had an impact on hepatic intrinsic clearance of $ Cl_{x} $BPA in rats and humans and measured values will be valuable for the development of PBPK models for use in exposure assessment..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Archives of toxicology - 96(2022), 3 vom: 24. Jan., Seite 783-792 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Plattard, N. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Chlorinated derivatives of bisphenol A |
| RVK: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s00204-021-03217-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2129452906 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2129452906 | ||
| 003 | DE-627 | ||
| 005 | 20230505222840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230505s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00204-021-03217-7 |2 doi | |
| 035 | |a (DE-627)OLC2129452906 | ||
| 035 | |a (DE-He213)s00204-021-03217-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a ELIB24 |q VZ |2 rvk | ||
| 084 | |a 44.40$jPharmazie$jPharmazeutika |2 bkl | ||
| 084 | |a 44.39$jToxikologie |2 bkl | ||
| 100 | 1 | |a Plattard, N. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatic metabolism of chlorinated derivatives of bisphenol A ($ Cl_{x} $BPA) and interspecies differences between rats and humans |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 | ||
| 520 | |a Abstract During chlorination treatments of drinking water, aqueous bisphenol A (BPA) can react with chlorine to form chlorinated derivatives of BPA (mono, di, tri and tetra-chlorinated derivatives) or $ Cl_{x} $BPA. These emerging substances are endocrine disruptors associated with obesity, type II diabetes (TD2M) and myocardial infarction. $ Cl_{x} $BPA are present in different human biological matrices but their toxicokinetics remain unknown. The aim of this study was to measure and compare the metabolic kinetics in the liver of four $ Cl_{x} $BPA (ClBPA, $ Cl_{2} $BPA, $ Cl_{3} $BPA and $ Cl_{4} $BPA) between compounds and between species (Sprague–Dawley rats vs humans). To estimate their metabolic constants (Vmax, Km, Intrinsic clearance), metabolic assays were performed in hepatocyte suspensions. Assays revealed that metabolic constants of $ Cl_{x} $BPA can greatly vary depending on substances and species. While ClBPA and $ Cl_{2} $BPA show similar unbound intrinsic clearances (ClintU) in rat incubation media, values for $ Cl_{3} $BPA and $ Cl_{4} $BPA are very different (3.109 and 0.684 mL/min/106 hepatocytes, respectively). Unlike in rats, human results are quite different as $ Cl_{3} $BPA and $ Cl_{4} $BPA have similar unbound intrinsic clearances, while ClBPA and $ Cl_{2} $BPA diverge (0.350 and 1.363 mL/min/106 hepatocytes, respectively). In both species, $ Cl_{2} $BPA and Cl3BPA have relatively similar clearances, and ClBPA is very different from $ Cl_{4} $BPA. Although we quantified the proportion of sulfo- and glucurono-metabolites, other metabolites may have been formed (e.g., glutathione, disulfate, or oxidative metabolites). This study showed that chlorination had an impact on hepatic intrinsic clearance of $ Cl_{x} $BPA in rats and humans and measured values will be valuable for the development of PBPK models for use in exposure assessment. | ||
| 650 | 4 | |a Chlorinated derivatives of bisphenol A | |
| 650 | 4 | |a Toxicokinetic | |
| 650 | 4 | |a Liver metabolism | |
| 650 | 4 | |a In vitro | |
| 650 | 4 | |a Hepatocytes | |
| 650 | 4 | |a Sprague–Dawley rats | |
| 650 | 4 | |a Human health | |
| 700 | 1 | |a Venisse, N. |4 aut | |
| 700 | 1 | |a Carato, P. |4 aut | |
| 700 | 1 | |a Dupuis, A. |4 aut | |
| 700 | 1 | |a Haddad, Sami |0 (orcid)0000-0001-8906-9693 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of toxicology |d Springer Berlin Heidelberg, 1930 |g 96(2022), 3 vom: 24. Jan., Seite 783-792 |h Online-Ressource |w (DE-627)25339015X |w (DE-600)1458459-1 |w (DE-576)072283319 |x 1432-0738 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2022 |g number:3 |g day:24 |g month:01 |g pages:783-792 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00204-021-03217-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2132 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2360 | ||
| 912 | |a GBV_ILN_2433 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2474 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4328 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 936 | r | v | |a ELIB24 |
| 936 | b | k | |a 44.40$jPharmazie$jPharmazeutika |q VZ |0 106423304 |0 (DE-625)106423304 |
| 936 | b | k | |a 44.39$jToxikologie |q VZ |0 106409328 |0 (DE-625)106409328 |
| 951 | |a AR | ||
| 952 | |d 96 |j 2022 |e 3 |b 24 |c 01 |h 783-792 | ||